Publications

Synthetic microneurotrophins: Neurotrophin receptors for therapeutics of neurodegenerative diseases.

Zota I, Chanoumidou K, Charalampopoulos I, Gravanis A.

Publication/Date/RefBr J Pharmacol. 2025;182:4466–4489.

Dynamics of myelin deficits in the 5xFAD mouse model for Alzheimer's disease and the protective role of BDNF.

Zota I, Chanoumidou K, Charalampopoulos I, Gravanis A.

Publication/Date/RefGlia. 2024;72:809–827.

Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease.

Zota I, Chanoumidou K, Gravanis A, Charalampopoulos I.

Publication/Date/RefFront Cell Neurosci. 2024;18:1422130.

Microneurotrophin BNN27 reduces astrogliosis and increases density of neurons and implanted neural stem cell-derived cells after spinal cord injury.

Georgelou K, Saridaki E-A, Karali K, Papagiannaki A, Charalampopoulos I, Gravanis A, Tzeranis DS.

Publication/Date/RefBiomedicines. 2023;11(4):1170.

The novel dehydroepiandrosterone derivative BNN27 counteracts the impairing effects of anesthetic ketamine on rats' non-spatial and spatial recognition memory.

Pitsikas N, Zoupa E, Gravanis A.

Publication/Date/RefBehav Brain Res. 2022;430:113937.

A microengineered Brain-Chip to model neuroinflammation in humans.

Pediaditakis I, Kodella KR, Manatakis DV, Le CY, Barthakur S, Sorets A, Gravanis A, Ewart L, Rubin LL, Manolakos ES, Hinojosa CD, Karalis K.

Publication/Date/RefiScience. 2022;25(8):104813.

Analgesic and Anti-Inflammatory Effects of the Synthetic Neurosteroid Analogue BNN27 during CFA-Induced Hyperalgesia.

Poulaki S, Rassouli O, Liapakis G, Gravanis G, Venihaki M.

Publication/Date/RefBiomedicines. 2021;9:1185.

Characterization of substantia nigra neurogenesis in homeostasis and dopaminergic degeneration: beneficial effects of the microneurotrophin BNN-20.

Mourtzi T, Dimitrakopoulos D, Kakogiannis D, Salodimitris C, Botsakis K, Meri DK, Anesti M, Dimopoulou A, Charalampopoulos I, Gravanis A, Matsokis N, Angelatou F, Kazanis I.

Publication/Date/RefStem Cell Res Ther. 2021;12(1):335.

Quantification of BNN27, a novel neuroprotective 17-spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration.

Tsika G, Tzatzarakis MN, Antimisiaris S, Tsoka P, Efstathopoulos P, Charalampopoulos I, Gravanis A, Tsilimparis M.

Publication/Date/RefPharmacol Res Perspect. 2021;9(2):e00724.

The beneficial role of the synthetic microneurotrophin BNN20 in a focal demyelination model.

Kalafatakis I, Patellis A, Charalampopoulos I, Gravanis A, Karagogeos D.

Publication/Date/RefJ Neurosci Res. 2021;99(5):1338–1351.

The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the D1/D2 dopaminergic receptor agonist apomorphine in rats.

Pitsikas N, Zoupa E, Gravanis A.

Publication/Date/RefPsychopharmacology (Berl). 2021;238(1):227–237.

Psychoactive properties of BNN27, a novel neurosteroid derivate, in male and female rats.

Kokras N, Dioli C, Paravatou R, Sotiropoulos MG, Delis F, Antoniou K, Calogeropoulou T, Charalampopoulos I, Gravanis A, Dalla C.

Publication/Date/RefPsychopharmacology (Berl). 2020;238(1):2435–2449.

Anti-neuroinflammatory, protective effects of the synthetic microneurotrophin BNN-20 in the advanced dopaminergic neurodegeneration of "weaver" mice.

Panagiotakopoulou V, Botsakis K, Delis F, Mourtzi T, Tzatzarakis MN, Dimopoulou A, Poulia N, Antoniou K, Stathopoulos GT, Matsokis N, Charalampopoulos I, Gravanis A, Angelatou F.

Publication/Date/RefNeuropharmacology. 2020;165:107919.

Neurosteroids as regulators of neuroinflammation.

Yilmaz C, Karali K, Fodelianaki G, Gravanis A, Chavakis T, Charalampopoulos I, Alexaki VI.

Publication/Date/RefFront Neuroendocrinol. 2019;55:100788.

Effect of topical administration of the microneurotrophin BNN27 in the diabetic rat retina.

Ibán-Arias R, Lisa S, Poulaki S, Mastrodimou N, Charalampopoulos I, Gravanis A, Thermos K.

Publication/Date/RefGraefes Arch Clin Exp Ophthalmol. 2019;257(11):2429–2436.

The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats.

Zoupa E, Gravanis A, Pitsikas N.

Publication/Date/RefNeuropharmacology. 2019;151:74–83.

The Synthetic Microneurotrophin BNN27 Affects Retinal Function in Rats With Streptozotocin-Induced Diabetes.

Ibán-Arias R, Lisa S, Mastrodimou N, Kokona D, Koulakis E, Iordanidou P, Kouvarakis A, Fothiadaki M, Papadogkonaki S, Sotiriou A, Katerinopoulos HE, Gravanis A, Charalampopoulos I, Thermos K.

Publication/Date/RefDiabetes. 2018;67(2):321–333.

DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway.

Alexaki VI, Fodelianaki G, Neuwirth A, Mund C, Kourgiantaki A, Ieronimaki E, Lyroni K, Troullinaki M, Fujii C, Kanczkowski W, Ziogas A, Peitzsch M, Grossklaus S, Sönnichsen B, Gravanis A, Bornstein SR, Charalampopoulos I, Tsatsanis C, Chavakis T.

Publication/Date/RefMol Psychiatry. 2018;23(6):1410–1420.

The novel synthetic microneurotrophin BNN27 protects mature oligodendrocytes against cuprizone-induced death, through the NGF receptor TrkA.

Bonetto G, Charalampopoulos I, Gravanis A, Karagogeos D.

Publication/Date/RefGlia. 2017;65(8):1376–1394.

BNN-20, a synthetic microneurotrophin, strongly protects dopaminergic neurons in the "weaver" mouse, a genetic model of dopamine denervation, acting through the TrkB neurotrophin receptor.

Botsakis K, Mourtzi T, Panagiotakopoulou V, Vreka M, Stathopoulos GT, Pediaditakis I, Charalampopoulos I, Gravanis A, Delis F, Antoniou K, Zisimopoulos D, Georgiou CD, Panagopoulos NT, Matsokis N, Angelatou F.

Publication/Date/RefNeuropharmacology. 2017;121:140–157.

The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts delay-dependent and scopolamine-induced recognition memory deficits in rats.

Pitsikas N, Gravanis A.

Publication/Date/RefNeurobiol Learn Mem. 2017;140:145–153.

Synthetic microneurotrophins in therapeutics of neurodegeneration.

Gravanis A, Pediaditakis I, Charalampopoulos I.

Publication/Date/RefOncotarget. 2017;8(6):9005–9006.

BNN27, a 17-Spiroepoxy Steroid Derivative, Interacts With and Activates p75 Neurotrophin Receptor, Rescuing Cerebellar Granule Neurons from Apoptosis.

Pediaditakis I, Kourgiantaki A, Prousis KC, Potamitis C, Xanthopoulos KP, Zervou M, Calogeropoulou T, Charalampopoulos I, Gravanis A.

Publication/Date/RefFront Pharmacol. 2016;7:512.

MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis.

Glajch KE, Ferraiuolo L, Mueller KA, Stopford MJ, Prabhkar V, Gravanis A, Shaw PJ, Sadri-Vakili G.

Publication/Date/RefPLoS One. 2016;11(10):e0164103.

Selective and differential interactions of BNN27, a novel C17-spiroepoxy steroid derivative, with TrkA receptors, regulating neuronal survival and differentiation.

Pediaditakis I, Efstathopoulos P, Prousis KC, Zervou M, Arévalo JC, Alexaki VI, Nikoletopoulou V, Karagianni E, Potamitis C, Tavernarakis N, Chavakis T, Margioris AN, Venihaki M, Calogeropoulou T, Charalampopoulos I, Gravanis A.

Publication/Date/RefNeuropharmacology. 2016;111:266–282.

Effects of novel synthetic microneurotrophins in diabetic retinopathy.

Lisa S, Iban-Arias R, Kokona D, Charalampopoulos I, Gravanis A, Thermos K.

Publication/Date/RefSpringerplus. 2015;4(Suppl 1):L25.

Dehydroepiandrosterone: an ancestral ligand of neurotrophin receptors.

Pediaditakis I, Iliopoulos I, Theologidis I, Delivanoglou N, Margioris AN, Charalampopoulos I, Gravanis A.

Publication/Date/RefEndocrinology. 2015;156(1):16–23.

Genetic dissection of neurotrophin signaling through the p75 neurotrophin receptor.

Charalampopoulos I, Vicario A, Pediaditakis I, Gravanis A, Simi A, Ibáñez CF.

Publication/Date/RefCell Rep. 2012;2(6):1563–1570.

Neurosteroids and microneurotrophins signal through NGF receptors to induce prosurvival signaling in neuronal cells.

Gravanis A, Calogeropoulou T, Panoutsakopoulou V, Thermos K, Neophytou C, Charalampopoulos I.

Publication/Date/RefSci Signal. 2012;5(246):pt8.

The neurosteroid dehydroepiandrosterone (DHEA) protects the retina from AMPA-induced excitotoxicity: NGF TrkA receptor involvement.

Kokona D, Charalampopoulos I, Pediaditakis I, Gravanis A, Thermos K.

Publication/Date/RefNeuropharmacology. 2012;62(5–6):2106–2117.

Neurosteroid dehydroepiandrosterone interacts with nerve growth factor (NGF) receptors, preventing neuronal apoptosis.

Lazaridis I, Charalampopoulos I, Alexaki VI, Avlonitis N, Pediaditakis I, Efstathopoulos P, Calogeropoulou T, Castanas E, Gravanis A.

Publication/Date/RefPLoS Biol. 2011;9(4):e1001051.

Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity.

Calogeropoulou T, Avlonitis N, Minas V, Alexi X, Pantzou A, Charalampopoulos I, Zervou M, Vergou V, Katsanou ES, Lazaridis I, Alexis MN, Gravanis A.

Publication/Date/RefJ Med Chem. 2009;52(21):6569–6587.

Dehydroepiandrosterone protects human keratinocytes against apoptosis through membrane binding sites.

Alexaki VI, Charalampopoulos I, Panayotopoulou M, Kampa M, Gravanis A, Castanas E.

Publication/Date/RefExp Cell Res. 2009;315(13):2275–2283.

Neurosteroid dehydroepiandrosterone exerts anti-apoptotic effects by membrane-mediated, integrated genomic and non-genomic pro-survival signaling pathways.

Charalampopoulos I, Margioris AN, Gravanis A.

Publication/Date/RefJ Neurochem. 2008;107(5):1457–1469.

Neurosteroids as modulators of neurogenesis and neuronal survival.

Charalampopoulos I, Remboutsika E, Margioris AN, Gravanis A.

Publication/Date/RefTrends Endocrinol Metab. 2008;19(8):300–307.

Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging.

Charalampopoulos I, Alexaki VI, Tsatsanis C, Minas V, Dermitzaki E, Lasaridis I, Vardouli L, Stournaras C, Margioris AN, Castanas E, Gravanis A.

Publication/Date/RefAnn N Y Acad Sci. 2006;1088:139–152.

G protein-associated, specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone.

Charalampopoulos I, Alexaki VI, Lazaridis I, Dermitzaki E, Avlonitis N, Tsatsanis C, Calogeropoulou T, Margioris AN, Castanas E, Gravanis A.

Publication/Date/RefFASEB J. 2006;20(3):577–579.

Dehydroepiandrosterone sulfate and allopregnanolone directly stimulate catecholamine production via induction of tyrosine hydroxylase and secretion by affecting actin polymerization.

Charalampopoulos I, Dermitzaki E, Vardouli L, Tsatsanis C, Stournaras C, Margioris AN, Gravanis A.

Publication/Date/RefEndocrinology. 2005;146(8):3309–3318.

Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation.

Alexaki VI, Charalampopoulos I, Kampa M, Vassalou H, Theodoropoulos P, Stathopoulos EN, Hatzoglou A, Gravanis A, Castanas E.

Publication/Date/RefFASEB J. 2004;18(13):1594–1596.

Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins.

Charalampopoulos I, Tsatsanis C, Dermitzaki E, Alexaki VI, Castanas E, Margioris AN, Gravanis A.

Publication/Date/RefProc Natl Acad Sci U S A. 2004;101(21):8209–8214.